Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Evette Mitkov

UNCOVERED: Minerva stock rises after securing 200m for schizophrenia drug trial | History Defined

Stock,Market,Growth,Vector,With,Green,Candlestick,Chart,And,Rising

Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.

What Happened: Minerva secured a securities purchase agreement with institutional investors providing up to $200 million in gross proceeds through a private placement. The arrangement includes $80 million in immediate funding through Series A preferred stock, plus up to $80 million more if Tranche A warrants are fully exercised.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.